Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15538
Abstract: Antiretroviral (ARV) therapy reduces inflammation and immune activation in people with HIV, but not down to the levels observed in people without HIV. Limited drug penetration within tissues has been argued as a potential mechanism… read more here.
Keywords: inflammation; darunavir tenofovir; intracellular exposure; inflammation intracellular ... See more keywords
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
Sign Up to like & getrecommendations! Published in 2023 at "Viruses"
DOI: 10.3390/v15051123
Abstract: Background: Since limited data are available, we aimed to compare the efficacy and durability of dolutegravir and darunavir in advanced naïve patients. Methods: Retrospective multicenter study including AIDS- or late-presenting (def. CD4 ≤ 200/µL) HIV-infected… read more here.
Keywords: dolutegravir darunavir; aids late; darunavir; late presenting ... See more keywords